What's Happening?
Longhorn Vaccines and Diagnostics is set to present new preclinical data on its novel human bispecific IgM monoclonal antibody, DRG5-BD11, at the European Society of Clinical Microbiology and Infectious
Diseases (ESCMID) 2026 conference. The antibody targets peptidoglycan and HSP16.3, showing broad antibacterial activity against gram-positive, gram-negative, and mycobacterial strains. This development highlights a potential new approach to addressing antimicrobial resistance and sepsis. The data demonstrates significant opsonophagocytic killing, with 82% effectiveness against E. coli and 74% against Mycobacterium smegmatis.
Why It's Important?
Antimicrobial resistance is a growing global health challenge, complicating the treatment of infections and increasing the risk of disease spread, severe illness, and death. Longhorn's DRG5-BD11 offers a promising alternative to traditional antibiotics, potentially enhancing the immune system's ability to clear diverse bacterial infections. This innovation could significantly impact the management of sepsis and drug-resistant pathogens, providing new tools for healthcare providers and improving patient outcomes.
What's Next?
Longhorn Vaccines will continue in vivo studies to evaluate the antibody's efficacy in clearing bacteria from the bloodstream and its protective effects in animal models. The company aims to advance its immunotherapy-based solutions for infectious diseases, with further research and development expected to refine and expand the application of DRG5-BD11. The outcomes of these studies could lead to new treatment protocols and enhance the global fight against antimicrobial resistance.
